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The criminal justice system bears a disproportionate burden of the HIV epidemic. Continuity of care is critical for HAART-based
prevention of HIV-related morbidity and mortality. This paper describes four major challenges to successful management of HIV
inthecriminaljusticesystem:relapsetosubstanceuse,homelessness,mentalillness,andlossofmedicalandsocialbeneﬁts.Eachof
these areas constitutes a competing priority upon release that demands immediate attention and diverts time, energy, and valuable
resources away from engagement in care and adherence to HAART. Numerous gaps exist in scientiﬁc knowledge about these issues
and potential solutions. In illuminating these knowledge deﬁcits, we present a contemporary research agenda for the management
of HIV in correctional systems. Future empirical research should focus on these critical issues in HIV-infected prisoners and
releasees while interventional research should incorporate evidence-based solutions into the criminal justice setting.
1.Introduction
The criminal justice setting provides vast opportunities for
earlydiagnosis,prevention,andtreatmentofHIV[1,2].One
in seven people living with HIV in the United States passes
through the criminal justice system (CJS) each year [3], and
incarceration is considered an independent risk factor for
HIV infection [4]. For those living with HIV, history of
incarceration is a strong predictor of nonadherence to HIV
treatment and care [5, 6].
Correctional facilities thus bear a disproportionate bur-
den of the HIV epidemic in the USA with a prevalence rate
of HIV 3–5 times higher than surrounding communities
[3, 7]. Though substantial need exists for management
of HIV during incarceration, it is complicated by equally
prevalent comorbid medical and psychiatric diseases, [8]
potential lack of privacy around HIV testing and treatment,
[9] inmates’ frequent mistrust of the healthcare system, [10]
and issues of control related to the prison environment itself
[11]. Perhaps as a result, only an estimated one-third of
HIV-infected inmates with a clinical indication for therapy
receive combination antiretroviral therapy (HAART) during
incarceration [12, 13].
Despite these obstacles, management of HIV in correc-
tional settings has been shown to be feasible, acceptable,
[10] and highly successful [7]. In Connecticut, an impressive
59% of HIV-infected inmates achieved an undetectable viral
load (i.e., <400 copies/mL) by the end of their incarceration
[14]. In this incarcerated cohort, clinical beneﬁt was derived
regardless of the type of HAART regimen prescribed [15].
Equal access to health care during incarceration also enables
impoverished and minority subpopulations to overcome
some healthcare disparities that exist outside prison walls
[13, 16]. The highly structured nature of prison contributes
to these successes, providing a relatively drug-free environ-
ment and granting opportunities to optimize medication
adherence through directly administered antiretroviral ther-
apy [17]. The provision of HAART in USA correctional
facilities is also supported by a Supreme Court decision that
established there cannot be “deliberate indiﬀerence” to the
health needs of inmates [18] and by state laws that protect
the rights to care of HIV-infected inmates in particular [19].2 AIDS Research and Treatment
Unfortunately, beneﬁts of prison-based HAART are rare-
ly sustained upon return to communities [14, 20, 21]. In the
Texas CJS, few prisoners ﬁlled prescriptions for their HIV
medications [22] or enrolled in an HIV clinic within 30 days
following release [23]. Upon release from prison, individuals
face diﬃculties adhering to HAART and HIV-related care
servicesbecausetheyareoftendistractedbybasicsubsistence
needsandtemptationsofdrugrelapse[24].Medicationnon-
adherence is associated with serious negative individual and
public health consequences. Although even intermittent
HAART adherence may provide some immunologic or vi-
rologic beneﬁt, [25] the Strategies for Management of Anti-
retroviral Therapy (SMART) study demonstrated that con-
tinuous therapy has superior long-term outcomes in terms
of AIDS-related morbidity and mortality [26].
There is a paucity of data evaluating barriers to sustained
antiretroviral therapy for HIV-infected persons transitioning
from the CJS to the community. In this review, we outline
major obstacles to continuous HIV care among populations
who interface with the CJS, both during incarceration and
after release. Major challenges include relapse to substance
use, housing instability, comorbid mental illness, and cover-
age gaps in medical and social beneﬁts. We brieﬂy describe
the signiﬁcance of each of these issues in general CJS or in
HIV-infected nonincarcerated populations and then explore
potential areas for future empirical and interventional re-
search. Rigorous scientiﬁc evaluation of these “knowledge
gaps” is critical for progress in the ﬁeld. Furthermore, suc-
cess of programs designed to facilitate transition between
prisons and communities hinges on bringing evidence-based
solutions into the criminal justice setting.
2. Methods
A search strategy was undertaken using PubMed, OvidSP,
and MEDLINE. The following key terms were used: HIV,
HAART, adherence, outcomes, prisoners, prison/jail, incarcer-
ated, inmates, criminal justice, corrections, transition, linkage,
and released. These were combined with terms relevant to
each topic of interest: substance, addiction, drugs, alcohol,
dependence/use/abuse, homelessness, housing, mental illness,
depression, insurance, Medicaid, and beneﬁts. Continuity of
care was deﬁned in terms of HAART adherence and enroll-
ment in HIV care upon release. Additional references from
seminal papers were reviewed to broaden the search and
assure that important contributions were not overlooked.
Articles were included if they were written in English and
were published in peer-reviewed journals between 1990–
2011.
3. Results
3.1. Relapse to Substance Use
3.1.1. Epidemiology of the Problem. Drug use and crime are
inextricably linked. In the United States, where the “war on
drugs” has devolved into a “war on drug users,” [27] drug-
related oﬀenses are punishable by incarceration. As a result,
theUSA,whichcontributesonly5%oftheworldpopulation,
holds25%oftheworldprisoners[28].Inthiscontext,almost
half of USA prisoners screen positive for marijuana, cocaine,
heroin, or methamphetamine at the time of their arrest [29],
and25%ofviolentoﬀendersareundertheinﬂuenceofdrugs
and alcohol when they commit crimes [30] .T h eC J Sb e a r sa
disproportionate burden of the epidemic of addiction, with
up to 65% of prison inmates meeting DSM-IV criteria for
drug or alcohol abuse or addiction [28, 30, 31]. In jails,
in which inmates are either unsentenced or sentenced to
shorter terms, women report even higher rates of substance
use disorders (SUDs) than their male counterparts [32]. Up
to 70% of HIV-infected prisoners meet criteria for opioid
dependence [33]. These ongoing and often untreated SUDs
play a major role in prison recidivism and likely contribute
to poor HIV outcomes after release.
3.1.2.AreasforFutureEmpiricalResearch. SUDshaveaseem-
ingly profound impact on the health outcomes of HIV-infe-
cted prisoners, for whom addiction-related lapses in HAART
continuity threaten virologic suppression after release. With
some notable exceptions described here, there have been
relatively few published studies regarding the eﬀect of SUDs
on HIV outcomes in released prisoners. A 2008 study of
HIV-infected reincarcerated jail detainees examined HAART
adherence between the time of prison release and reincar-
ceration. Findings revealed that those subjects who discon-
tinued HAART were three times more likely to have also
relapsed to marijuana or injection drug use between incar-
cerations [34]. Among HIV-infected injection drug users in
Vancouver, any alcohol use or incarceration in the prior six
months was associated with poor HAART adherence and
worse virologic outcomes [35]. In a smaller study of 30
HIV-infected recently released prisoners, only 18 (60%) were
enrolled in HIV primary care 21 days after incarceration.
Enrollment in primary care was associated with abstinence
from alcohol though this association did not reach statistical
signiﬁcance, likely owing to the small sample size [36]. Other
published research on reduced uptake in HIV care after pris-
on release has not assessed the important contribution of
SUDs to discontinuous care [22, 23].
Extrapolating from studies of community-based subjects
with HIV outside of the CJS, alcohol use is associated with
decreased initiation of and adherence to HAART as well as
increased rates of virologic failure [37]. Similarly, relapse to
drug use, especially injection drugs and crack cocaine, has
beenassociatedwithdecreasedHAARTadherence,decreased
engagement in HIV care, and increased risk of developing
AIDS-deﬁning conditions [5, 38]. The ﬁeld would beneﬁt
from parallel research on the eﬀect of SUDs on HIV biologic
outcomes among prisoners and releasees living with HIV.
3.1.3. Areas for Future Interventional Research. Despite over-
whelming demonstrated need, substance abuse treatment
programs during incarceration are relatively nonexistent
[39]. As few as 11% of inmates with SUDs receive treatment
for addiction during their incarceration with an emphasis
insteadoneducation,detoxiﬁcation,andabstinence[28,40].
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risk for relapse to drugs or alcohol [41–43] with associated
drug-related recidivism to prison [44] and excess mortality
due to drug overdose [45, 46].
Treatment of SUDs is clearly beneﬁcial for relapse pre-
vention but may also improve engagement in HIV care. In-
deed, two recent interventions [33, 47] have demonstrated
thatopioidagonisttherapiesinitiateduponreleaseareeffect-
ive at preventing relapse to opioid use and secondarily main-
tain HAART-related beneﬁts achieved during incarceration.
Since persistent virologic suppression is associated with dec-
reased risk of HIV transmission, treatment of SUDs might,
indirectly, be an eﬀective secondary prevention measure for
HIV [48, 49]. Treatment of SUDs is necessary but may be
insuﬃcient alone because of the many other complex social
and behavioral stressors that simultaneously disrupt care in
this patient population [28, 50]. These will be addressed
systematically in the following sections.
3.2. Comorbid Mental Illness
3.2.1. Epidemiology of the Problem. Substance use disorders
are often concurrent and synergistic with mental health dis-
orders and it may be diﬃcult to disentangle the two issues.
Over three-quarters of jail inmates with mental health dis-
orders meet criteria for substance dependence or abuse [51].
Mental illness is highly prevalent in the CJS overall with
14–24% of prison and jail inmates reporting recent mental
health problems [51]. Prevalence of psychiatric disorders is
even higher among female compared to male inmates [32,
51]. The convergence of mental health disorders and HIV is
especially evident in the CJS. Among inmates in the Texas
Department of Criminal Justice, psychiatric disorders were
more common among PLWHA compared to their un-
infected peers [52].
3.2.2. Areas for Future Empirical Research. Little is known
about the eﬀects of mental health disorders on HIV out-
comes in dually diagnosed persons in the CJS. In non-
CJSsettings, however,treatmentofpsychiatriccomorbidities
has a profound impact on adherence to antiretroviral ther-
apy. Several studies have examined the association of dep-
ression with HAART nonadherence in community-based
cohorts. Among HIV-infected women, depression has been
associated with decreased virologic response to HAART,
higher likelihood of immunologic failure, and higher risk for
all-cause mortality [53]. The longitudinal Multicenter AIDS
Cohort Study of men who have sex with men showed that
depression increased risk of interrupting or discontinuing
HAART [54].
Furthermore, relatively few studies have examined asso-
ciations between serious mental illness (SMI) and HAART
adherence despite signiﬁcant epidemiologic overlap between
HIV and SMI. SMI includes the diagnoses of schizophre-
nia, schizoaﬀective disorder, bipolar depression, and major
depression with psychotic features. Adherence to psychiatric
medications among SMI patients ranges between 40–60%,
suggesting that adherence to HAART in these populations
might also be problematic [55]. This has especially troubling
implications in the CJS where both HIV and SMI are highly
concentrated.Approximately14–22%ofinmatesinstateand
federal prisons/jails meet criteria for mania and 8–17%
meet criteria for a psychotic disorder [51]. Interestingly, in
one study of 47 community-based participants with SMI
and HIV in Los Angeles, the mean adherence rate to anti-
retrovirals (proportion of prescribed doses taken) was 66%
with surprisingly almost half of participants having a >90%
adherenceratetoHAART.Theauthorsnotethatthissigniﬁes
that HAART adherence rates are similar to adherence rates
among people living with HIV but without SMI in commu-
nity clinics, implying that diagnosis of comorbid SMI should
not preclude HIV treatment [55] .T h i s ,h o w e v e r ,w a so n l y
onesmallstudyofcommunity-basedpatientswithcomorbid
SMI and HIV. To our knowledge, there are no published
studies examining antiretroviral or psychiatric medication
adherence among subjects with both SMI and HIV in the
CJS. Given the large overlap between HIV and mental
health disorders in this setting, more research is needed on
correlates of HAART adherence in the correctional popula-
tion with dual diagnoses.
3.2.3. Areas for Future Interventional Research. Management
of mental illness in correctional settings is an understudied
but critical issue for people living with HIV. Among dep-
ressed HIV-infected patients in a non-correctional managed
care setting, those who were treated with selective serotonin
reuptake inhibitors for depression were more likely to be
>95% adherent to HAART medications than those with un-
treated depression [56]. In addition, depressed patients ad-
herent to psychiatric medications had similar HAART ad-
herence and HAART-related outcomes as non-depressed
people living with HIV on HAART [56]. Another study of
injection drug users enrolled in a trial of directly admin-
istered antiretroviral therapy found that improvements in
depressivesymptomswereassociatedwithincreasedHAART
adherence and increases in CD4 cell counts [57]. Treatment
ofdepressionandseriousmentalillnesscanleadtoimproved
HIV outcomes and HAART adherence rates that reach parity
with people living with HIV but without mental illness
[55, 56].
Unfortunately, even if inmates are engaged in psychiatric
care during incarceration, treatment of mental illness in the
CJS is often disrupted after release to communities. Upon
initial release, suicide is common among former inmates,
ranking among the top 5 causes of death in one study of
released prisoners in Washington state and indicating inade-
quate treatment of mental health disorders during this crit-
ical transition period [45]. System-based structural barriers
to care may be seemingly insurmountable. Understaﬃng of
outpatient psychiatric clinics and insurer-based restrictions
on mental health coverage can lead to the unavailability of
treatment for mentally ill persons in the community. This
is of grave concern for mentally ill patients with HIV be-
cause, as aforementioned, undertreated mental illness is re-
lated to decreased HAART adherence, worse biological out-
comes, and increased risk of death [45, 53, 54, 57]. In
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prison recidivism among both HIV-infected and uninfected
individuals [21, 51, 58].
Methods to coordinate psychiatric services upon release
from correctional settings are necessary. Formal case man-
agement services that enhance linkages to psychiatric care
may secondarily improve adherence to HAART, and research
is currently ongoing in this ﬁeld [59]. Other strategies of di-
verting mentally ill oﬀenders to treatment rather than incar-
ceration through the use of mental health courts have been
shown successful in engaging individuals in psychiatric care
and cost savings compared to incarceration. The impact of
theseprogramsonHIVoutcomesisnotknownbutwouldbe
an important area of interest in future interventional studies
[58, 60].
3.3. Homelessness
3.3.1. Epidemiology of the Problem. A relative lack of mental
health services in the community combined with the “War
on Drugs” has resulted in the shuttling of mentally ill per-
sons between homelessness and incarceration. Incarceration
increases the risk of homelessness through loss of employ-
ment, loss of housing, and disruption of social support or
community resources [61, 62]. Conversely, homelessness in-
creases incarceration risk through common behaviors, in-
cluding substance use and transactional sex [61–65]. Home-
lessness itself is also frequently criminalized, such that pub-
lic intoxication, loitering, and vagrancy are behaviors pun-
ishablebyincarceration.Approximately23–68%ofhomeless
individuals have a history of incarceration [61, 63]. Pre-
valence of homelessness prior to incarceration is twice as
high among those with mental health problems as those
without(13.2%versus6.3%instateprisons)[51].Asaresult,
a revolving door between homelessness and incarceration is
common, especially among those with mental illness or sub-
stance abuse issues [58, 61, 66].
Among PLWHA, homelessness and unstable housing
have been associated with poor HIV outcomes including
worse adherence to HAART, fewer ambulatory care visits,
and increased risk of death [67–70]. A case-control study of
the impact of housing on survival of persons with AIDS not-
ed that 9.8% of persons were homeless at time of AIDS di-
agnosis and that 5-year survival was far worse for those who
were homeless compared to those who were housed (67%
versus 81%, resp.) [69]. This study also noted that antiretro-
viral use was lower among the homeless compared to the
housed and that provision of housing improved survival
[69]. In Chicago, provision of housing to HIV-infected ho-
meless subjects with recent hospitalizations improved AIDS-
free survival at 12 months [67]. Similarly, a prospective
three-city study (in Baltimore, Chicago, and Los Angeles)
randomized homeless or unstably housed PLWHA to imme-
diate enhanced rental assistance versus customary housing
services. In an intention to treat analysis, there was no
diﬀerence between the two groups in terms of adherence to
HAART, HIV RNA levels, or CD4 lymphocyte counts. In an
“as-treated”analysis;however,thosewhoremainedhomeless
at followup were signiﬁcantly more likely to have a higher
HIV RNA viral load, regardless of randomization group
[70]. Homelessness or unstable housing can have a profound
impact on HAART adherence because homeless individuals
are often distracted by trying to meet basic needs of food
and shelter. The homeless often have diﬃculty safely storing
medications although few current ﬁrst-line antiretroviral
regimensrequirerefrigeration.Nevertheless,HAARTmaybe
successfully initiated in homeless or marginally housed pa-
tients: the three-city study did ﬁnd that 78% of the home-
less or unstably housed self-reported 100% past 2-day ad-
herence to HAART [71].
The eﬀects of homelessness on HAART adherence are
often confounded by the presence of comorbid mental ill-
ness or SUDs. Homeless or unstably housed individuals are
less likely to be adherent to HAART if they have recent sub-
stance use or higher depression scores [71]. A randomized
controlled trial of HIV-infected homeless or marginally
housed adults with depression found that providing antide-
pressants increased probability of achieving HIV virologic
suppression [72]. Thus, treatment of HIV among the home-
less or marginally housed can be complicated by comorbid
substanceuseormentalhealthissuesbutproactivetreatment
of these comorbid conditions can improve HIV outcomes.
3.3.2. Areas for Future Empirical Research. Although these
studies have demonstrated the negative impact of homeless-
ness on HAART adherence, there is no scientiﬁc literature
concerning the impact of homelessness on recently incarcer-
ated, HIV-infected populations. Given the high prevalenceof
homelessnessafterreleasefromprisonandthedemonstrated
beneﬁcial eﬀects of housing on social, psychiatric, addiction
and HIV-related outcomes, future research should focus on
correlates of risk of homelessness among recently-released
prisoners and jail detainees.
Obtaining housing constitutes a top priority often ex-
pressed by HIV-infected released prisoners. Many prisoners
return to communities plagued by poverty, unemployment,
and violence—the same communities from which they were
incarcerated. They must attempt to navigate this environ-
mentwhilesimultaneouslymanagingthemorepersonalstre-
ssesofreunitingwithparents,partners,andchildrenafterin-
carceration. Ideally, these relationships would support posi-
tive health promotion. All too often, however, these relation-
ships are aﬄicted with addiction and interpersonal violence
that only exacerbate stress and interfere with health-seeking
behaviors. Returning prisoners must also attempt to manage
comorbid medical illnesses, like diabetes and hypertension,
whichcanbecomeimmediatelylife-threateningwhenunder-
treated,especiallyinthecontextofhomelessness.Theseover-
lapping stresses (poverty, neighborhood characteristics, in-
terpersonal relationships, and comorbid chronic medical
conditions) may be important to individuals’ health after
prison release and likely contribute to prison recidivism. Un-
fortunately, there have been few published studies to date
around homelessness and HIV-related continuity of care
after release, thus limiting our discussion on these topics.
Future studies should address the impact of homelessness
and social instability, as more broadly deﬁned, on healthcare
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3.3.3. Areas for Future Interventional Research. Despite the
strong association between homelessness and incarceration,
strategies addressing the housing needs of HIV-infected
inmates upon release have not been well studied. A possible
strategy that may improve comorbid substance use or psy-
chiatric disorders as well as recidivism is a Housing First
approach. Contrary to traditional substance abuse or mental
health treatment programs which require strict adherence to
treatment in order to maintain housing, Housing First pro-
grams provide immediate access to permanent housing
without any prerequisites for psychiatric treatment or sobri-
ety. Among homeless or marginally housed persons with
serious mental illness, Housing First programs have been
successful in improving residential status and decreasing use
of inpatient, emergency, and criminal justice system services
[73, 74]. Although Housing First models have not been
studiedintheHIV-infectedrecentlyincarceratedpopulation,
its successes among vulnerable populations with serious me-
ntal illness or substance use disorders suggest it may be a
promising strategy for this group.
Other possible interventions to improve HIV outcomes
amonghomelessormarginallyhousedreleaseesinvolveimp-
roving engagement to care through increased supportive
services. In San Francisco, a clinic specializing in supporting
recently released inmates in the transition back to the com-
munity was noted to successfully engage a population in
which 38% were homeless [75]. The clinic employed a
full-time community health worker who attended parole
meetings and provide enhanced case management services
for clinic patients. Although the San Francisco clinic targeted
non-HIV-infectedpersons,thetransitionsclinicmayserveas
a model for maintaining HIV-infected, homeless individuals
in care. Currently, the HRSA-funded Enhancing Linkages to
HIV Primary Care and Services in Jail Settings Initiative is
studying the impact of enhanced case management services
that can include housing services [59]. Although enhanced
case management services may not improve linkage to care
in all settings, [76] its eﬃcacy among homeless populations
has not yet been studied.
Fortunately, homelessness is a modiﬁable risk factor that
couldbepreventedwitheﬀectivedischargeplanningservices.
Transitional case management programs should proactively
address housing instability as part of a comprehensive pack-
age of social services, recognizing the extreme vulnerability
during this period of movement between prisons and com-
munities. Provision of housing is, like many of the other
issues addressed here, not a stand-alone problem.
3.4. Loss of Medical and Social Beneﬁts
3.4.1. Epidemiology of the Problem. In the current USA
healthcare system, where medical care is predominantly fun-
ded by third-party payors, gaps in insurance coverage dur-
ing incarceration contribute to fragmentation of care upon
release.Byvirtueoftheirsocioeconomicormedicaldisability
status, most inmates with health insurance have Medicaid
prior to incarceration. Medicaid prohibits any use of fed-
eral funds for medical or psychiatric care of inmates in
jails and prisons. Most states (>90%) terminate Medicaid
coverage during incarceration [77]. For those who qualify
for Medicaid by virtue of their receiving social security
income, termination, rather than suspension, of beneﬁts
is almost guaranteed [77, 78]. Termination signiﬁes that
inmates are completely removed from Medicaid rolls and
are required to reapply. Because of the diﬃculties former
inmates face in obtaining employment, employment-based
health insurance is not a reliable option. In addition, job
applications for even the most menial opportunities often
require a permanent address, which many former inmates
cannotprovide[79].Duringincarceration,manyothersocial
beneﬁts including food stamps, state-subsidized housing,
and temporary assistance for needy families are also sus-
pended or discontinued [80].
As a result, many inmates are left with gaps in medical
and social beneﬁt coverage upon release from prison. Reap-
plication procedures for Medicaid can be initiated as early as
45–90 days prior to expected release [78]b u tr e q u i r ep h o t o
identiﬁcation and other documentation that are sometimes
logistically diﬃcult for former inmates to obtain. Further-
more, released prisoners often are returned to communities
late at night or on weekends when services are closed [79].
Because of these barriers, a survey of 511 women leaving
New York’s jails found that only half of the participants had
obtainedhealthinsurancebyoneyearafterrelease,regardless
of whether or not they had comorbid conditions like asthma,
diabetes, or HIV that required ongoing medical care [81].
Interruptions in coverage result in a greater reliance on
“free” episodic emergency and hospital-based care [82]a n d
decreased engagement with mental health services for the
mentally ill [83]. Perhaps because having medical insurance
is a marker of social stability, subjects who obtained health
insurance coverage following release were 69% less likely to
berearrestedforanycauseand91%lesslikelytoberearrested
ondrug-relatedchargesatthetimeoffollow-upcomparedto
those without health insurance [44].
For HIV-infected released prisoners, continuity of med-
ical coverage is especially crucial for continued provision of
HAART. In the past, coverage for antiretrovirals was dismal:
in a 1994 study, 19% of HIV-infected prisoners reported try-
ingtogetrearrestedjusttoobtainprison-basedHIVcarethat
was seemingly not available to them in the community after
release [84]. Fortunately today, coverage gaps are bridged by
the AIDS Drug Assistance Program (ADAP) which, under
HRSA’s Ryan White HIV/AIDS Treatment Modernization
Act Part B, acts as the “payor of last resort.” [85] Baillargeon
et al. [22] estimated that 100% of HIV-infected inmates who
receivedHAARTduring incarcerationinTexaswouldqualify
for ADAP. Over the past decade, ADAP has made signiﬁcant
inroads into covering this vulnerable population.
3.4.2. Areas for Future Empirical Research. Beyond the avail-
ability of medication assistance programs, there remains
a signiﬁcant knowledge gap about why and how released
prisoners experience decreased persistence in HIV care.
Certainly the problem is multifactorial and complex: this
populationisoftenmarginalizedfromthemainstreammedi-
cal community because of active drug use, mental illness,6 AIDS Research and Treatment
or HIV-related stigma prior to and following incarceration.
Even in Canada, in which a nationalized healthcare sys-
tem removes signiﬁcant insurance-related barriers to care,
released prisoners report problems obtaining appointments
with an HIV clinician after return to the community [86].
These appointment delays have been associated with lapses
in medication adherence lasting 1–3 days which, especially
in the case of antiretrovirals with low genetic barriers to
resistance, may be suﬃcient to result in virologic failure.
Other lapses in HAART adherence have been speciﬁcally
linked to points of custody transfers (i.e., movement from
police stations or court to correctional facilities, transfer
from prisons to communities.) [86]. Future research around
correlates of decreased persistence in HIV care for released
prisoners should incorporate mixed methods with qualita-
tive interviews of released prisoners to increase granularity
of available data.
3.4.3. Areas for Future Interventional Research. In spite of
signiﬁcant safety nets for people living with HIV, there
remain gaps in medical coverage after release that present
barriers to continuous HIV care. These should be addressed
by future interventions. Delays in completing and processing
ADAP applications are a limiting factor in HIV-infected
recently released prisoners beneﬁting from the program. In
a cross-sectional mixed methods study of 105HIV-infected
recently released prisoners in Florida, 19% reported that the
paperwork required to obtain medical care, insurance, and
HAART presented a major obstacle to care [79]. Of 177HIV-
infected reincarcerated jail inmates, 48% had no health
insurance and only 61% had ADAP when living in the
community [34]. Of those who reported taking HAART
in the community, 19% never once saw an HIV provider
during the 12-month-observation period [34]. Conversely,
inmates who received assistance with ADAP applications
in Texas prior to release were three times more likely to
ﬁll HAART prescriptions within 10 days after release [22].
This latter study in Texas was one of the few to date
that incorporated assistance with ADAP applications into a
comprehensive transitional case management program. Fu-
ture interventions should include similar programs while
taking an evidence-based approach to measuring important
outcomes, including HAART adherence, continuity of care,
enrollment in an HIV clinic, prison recidivism, and HIV-
associated morbidity.
4. Summary
Each year, almost 10 million people are released from USA
jails and prisons to the community [3, 44]. A small but
signiﬁcant proportion of these released prisoners are living
with HIV, a disease best managed with lifelong combination
antiretroviral therapy in regular consultation with an HIV
specialist. Continuity of care is critical for prevention of
HIV-related morbidity and mortality but faces numerous
obstacles in the transitions from community to prison and
back to the community. In this paper we explored four
major challenges to successful management of HIV in
correctional populations: relapse to substance use, mental
illness, homelessness, and loss of medical and social beneﬁts.
Each of these areas constitutes a competing priority upon
release that demands immediate attention and diverts time,
energy, and scarce resources away from engagement in care.
In this era of HAART, HIV may be perceived as a chronic,
asymptomatic disease of less urgent interest to returning
prisoners than meeting basic subsistence needs, coping with
debilitating psychiatric illnesses or meeting the physical and
mental demands of powerful addictions. These barriers to
continuity of HIV care and HAART adherence must be ad-
dressedforthesakeoftheindividualandfromapublichealth
standpoint.
The numerous outstanding knowledge gaps and solution
gaps concerning HIV outcomes in criminal justice popula-
tions also present exciting academic opportunities for future
research. We have attempted to shed light on these gaps
in support of a contemporary research agenda. Evidence-
based examinations of the problems and solutions facing
criminal justice populations are critical to progress in the
management of HIV in correctional systems.
5. Discussion
Our review of the literature suggests that linkages from
prison-based to community HIV care are critical for main-
taining the beneﬁts of HAART achieved during incarcera-
tion. There is ongoing debate in the criminal justice ﬁeld
about how best to design transitional interventions to ad-
dress these complex issues that otherwise disrupt care for
returning prisoners. Options proposed thus far include in-
tensive case management, supportive housing, opioid substi-
tution therapy, directly administered antiretroviral therapy,
medication adherence support, or combinations therein. We
advocate that, regardless of methodology, the most eﬀective
interventions require signiﬁcant breadth to address all of the
barriers that manifest during transfer from prison to the
community.
Unfortunately, there are signiﬁcant logistical constraints
to introducing evidence-based interventions into correction-
al systems either during incarceration or prior to release.
Inmates are often transitory, cycling frequently and rapidly
between jails and communities or among various correc-
tional facilities. This migratory pattern provides a narrow
window in which to introduce and assess any given inter-
vention. Constraints may also be imposed by a correctional
system itself that enforces strict privacy protection measures
(especially regarding HIV serostatus) and is subject to state,
or federally based budgetary limitations. Even outside prison
walls, and thus, technically outside of correctional systems,
released prisoners may be diﬃcult subjects in longitudinal
studies because they often experience high rates of attrition.
Strategies for collaboration between academic centers of
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must work to develop geographically and culturally appro-
priate interventions that are highly tailored to individual
needs. Perhaps most diﬃcult, future research should attempt
to deconstruct structural barriers to persistence in HIV care
that include termination of medical/social beneﬁts during
incarceration,minimallinkagestocommunity-basedpsychi-
atric and HIV primary care, and often-absent treatment for
substance use disorders. As providers and clinical research-
ers, we must act as advocates for this often silenced and mar-
ginalized population living with HIV.
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